CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:High-Precision Intrinsic Interactome Elucidation of Chimeric Antigen Receptors via Photocatalytic Micromapping (μMap-CAR).
High-Precision Intrinsic Interactome Elucidation of Chimeric Antigen Receptors via Photocatalytic Micromapping (μMap-CAR).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是治疗多种血液系统恶性肿瘤的强效方式。然而,其在更广泛疾病情境、尤其实体瘤中的疗效有限,凸显了改进CAR设计以增强效力、持久性和安全性的必要性。CAR的重要设计特征已从T细胞受体(TCR)及其相互作用网络的深入认识中获益。推动CAR-T 疗法进步需要新的、具有功能意义的蛋白质来支持工程设计。迄今,CAR周围实际的分子微环境仍未得到充分描述,主要原因是缺少足够精准且灵敏的表征方法。
本研究介绍Map-CAR,这是一种高分辨率光催化近邻标记平台,通过关键方法优化,可直接解析活T细胞表面CAR的相互作用组。该平台在静息及模拟活化条件下的CAR-T 细胞模型中均表现稳定。Map-CAR灵敏度较高,可检测CAR内域改变后相互作用组的差异,并将受扰信号网络直接关联至CAR组分。
我们进一步首次在原代T细胞中绘制高分辨率的内源CAR相互作用组,确定不同供者间共有的相互作用分子,并通过超分辨率显微成像和CAR-T 活化扰动实验验证候选分子。该平台是用于CAR相互作用组分析的强大通用工具,也为近邻导向的CAR工程设计提供可操作靶点。
Chimeric Antigen Receptor T-cell (CAR-T) therapies represent a powerful modality for treating a variety of hematological cancers.
However, limited efficacy in broader disease contexts, particularly solid tumors, underscores the need for improved CAR design to enhance potency, persistence, and safety. Key design features of CARs have been profoundly informed by extensive knowledge of the T-cell receptor (TCR) and its interactome.
To advance CAR-T therapies, new functionally relevant proteins are needed to support engineering efforts. Until now, the actual molecular microenvironment surrounding CARs has remained poorly defined, chiefly due to the lack of a characterization method with the required precision and sensitivity.
Herein, we introduce Map-CAR, a high-resolution photocatalytic proximity labeling platform featuring key methodological optimizations that enable direct elucidation of the CAR interactome on live T-cell surfaces. The platform performs robustly in a model CAR-T cell system under both resting and simulated activation conditions. The high sensitivity of Map-CAR allows interrogation of interactome differences upon CAR endodomain alterations, linking perturbed signaling networks directly to CAR components.
We further deliver the first high-resolution intrinsic CAR interactome in primary T-cells, defined by shared interactors across donors, and validate candidates via super-resolution microscopy and CAR-T activation perturbation. This platform constitutes a powerful, broadly applicable tool for CAR interactome profiling while also providing actionable targets for proximity-guided CAR engineering applications.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。